A general finding is that obese patients that fulfill the criteria for MetS presenting low IGF-1 plasma levels, tend to develop a worse cardiovascular disease outcome than those with mid-normal to high-normal IGF-1 level [32]. This evidence concerns the gene IGF1 and cardiovascular disorder.